<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ibrahim AS</submitter><funding>NIAID NIH HHS</funding><pagination>721-7</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC547300</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>49(2)</volume><pubmed_abstract>Rhizopus oryzae is the most common cause of zygomycosis, a life-threatening infection that usually occurs in patients with diabetic ketoacidosis. Despite standard therapy, the overall rate of mortality from zygomycosis remains >50%, and new strategies for treatment are urgently needed. The activities of caspofungin acetate (CAS) and other echinocandins (antifungal inhibitors of the synthesis of 1,3-beta-D-glucan synthase [GS]) against the agents of zygomycosis have remained relatively unexplored, especially in animal models of infection. We found that R. oryzae has both an FKS gene, which in other fungi encodes a subunit of the GS synthesis complex, and CAS-susceptible, membrane-associated GS activity. Low-dose but not high-dose CAS improved the survival of mice with diabetic ketoacidosis </pubmed_abstract><journal>Antimicrobial agents and chemotherapy</journal><pubmed_title>Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.</pubmed_title><pmcid>PMC547300</pmcid><funding_grant_id>R03 AI054531</funding_grant_id><funding_grant_id>R01 AI063503</funding_grant_id><funding_grant_id>KO8 AI060641-01</funding_grant_id><funding_grant_id>K08 AI060641</funding_grant_id><pubmed_authors>Spellberg B</pubmed_authors><pubmed_authors>Brown K</pubmed_authors><pubmed_authors>Ibrahim AS</pubmed_authors><pubmed_authors>Douglas CM</pubmed_authors><pubmed_authors>Edwards JE</pubmed_authors><pubmed_authors>Bowman JC</pubmed_authors><pubmed_authors>Avanessian V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.</name><description>Rhizopus oryzae is the most common cause of zygomycosis, a life-threatening infection that usually occurs in patients with diabetic ketoacidosis. Despite standard therapy, the overall rate of mortality from zygomycosis remains >50%, and new strategies for treatment are urgently needed. The activities of caspofungin acetate (CAS) and other echinocandins (antifungal inhibitors of the synthesis of 1,3-beta-D-glucan synthase [GS]) against the agents of zygomycosis have remained relatively unexplored, especially in animal models of infection. We found that R. oryzae has both an FKS gene, which in other fungi encodes a subunit of the GS synthesis complex, and CAS-susceptible, membrane-associated GS activity. Low-dose but not high-dose CAS improved the survival of mice with diabetic ketoacidosis </description><dates><release>2005-01-01T00:00:00Z</release><publication>2005 Feb</publication><modification>2025-04-19T11:30:46.294Z</modification><creation>2019-03-27T01:08:33Z</creation></dates><accession>S-EPMC547300</accession><cross_references><pubmed>15673756</pubmed><doi>10.1128/aac.49.2.721-727.2005</doi><doi>10.1128/AAC.49.2.721-727.2005</doi></cross_references></HashMap>